SynAct Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:8F8 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
19 Dec 25	Buy€6,652	Anders Kronborg	Individual		3,470	€1.92
19 Dec 25	Buy€6,640	Thomas Jonassen	Individual		3,529	€1.88

Insider Trading Volume

Insider Buying: 8F8 insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 8F8?
Owner Type	Number of Shares	Ownership Percentage
Institutions	5,616,851	10%
Individual Insiders	6,047,141	10.8%
Private Companies	15,436,068	27.6%
General Public	28,901,601	51.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 16 shareholders own 48.39% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.63%	Sanos Bioscience A/S	5,390,981	€8.7m	0%	no data
9.47%	Avanza Fonder AB	5,303,713	€8.6m	-6.97%	0.1%
9.47%	NBCD A/S	5,302,732	€8.6m	0%	no data
5.25%	Thomas Ringberg	2,940,535	€4.8m	0%	no data
4.61%	Bioinvest Sverige Ab	2,581,130	€4.2m	0%	no data
3.92%	Thomas Jonassen	2,195,574	€3.6m	477%	no data
3.86%	TJ Biotech Invest ApS	2,161,225	€3.5m	0%	no data
0.62%	Jeppe Ovlesen	346,736	€562.0k	0%	no data
0.56%	SEB Investment Management AB	311,951	€505.6k	0%	no data
0.42%	Thomas Boesen	236,529	€383.4k	0%	no data
0.24%	Sten Scheibye	132,093	€214.1k	0%	no data
0.14%	James Knight	77,452	€125.5k	0%	no data
0.12%	Anders Kronborg	67,255	€109.0k	5.44%	no data
0.06%	Bjorn Westberg	33,560	€54.4k	0%	no data
0.031%	Sten Sorensen	17,407	€28.2k	0%	no data
0.0021%	State Street Global Advisors, Inc.	1,187	€1.9k	6.46%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/13 20:17
End of Day Share Price	2026/03/13 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SynAct Pharma AB is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Patrik Ling	DNB Carnegie
Jyoti Prakash	Edison Investment Research
Carl Ramanius	Redeye